Exertional Dyspnoea With Increased Filling Pressure - Mechanisms And Treatment Strategies
Funder
National Health and Medical Research Council
Funding Amount
$387,793.00
Summary
Patients with early heart disease often present with shortness of breath with exercise, as myocardial reserve at that stage is usually sufficient to maintain normal function at rest . Indeed, much myocardial dysfunction may originate from the modern lifestyle, including inactivity, obesity, the metabolic syndrome and type II diabetes. The potential benefits of making a definitive early diagnosis are large, because it seems more likely that an impact can be made on the disease process (and theref ....Patients with early heart disease often present with shortness of breath with exercise, as myocardial reserve at that stage is usually sufficient to maintain normal function at rest . Indeed, much myocardial dysfunction may originate from the modern lifestyle, including inactivity, obesity, the metabolic syndrome and type II diabetes. The potential benefits of making a definitive early diagnosis are large, because it seems more likely that an impact can be made on the disease process (and therefore, outcome) than with late stage disease. Current treatment strategies are expensive and because they are directed at end-organ damage (heart failure, heart attacks etc), rather ineffective. This multispecialty, multidisciplinary group will undertake a series of unique studies aimed at identifying early cardiovascular disease. The strategy will involve detection of abnormal filling behaviour at stress echocardiography, with randomization into longterm and short-term trials to examine various therapeutic strategies. Sensitive new cardiovascular imaging techniques will be used to detect preclinical abnormalities in the structure and function of the heart and vasculature, facilitating a mechanistic understanding of the process of increasing filling pressure with exercise.Read moreRead less
Preclinical Relaxin Therapy To Reverse Cardiac Fibrosis And Gain Functional Benefits
Funder
National Health and Medical Research Council
Funding Amount
$724,754.00
Summary
Cardiac fibrosis is a key factor promoting heart disease and onset of complications including arrhythmias and heart failure. There is urgent and unmet need of drugs that can reverse fibrosis. By documenting anti-fibrotic action of a peptide hormone relaxin, CIA and his team will test therapeutic effect of relaxin in heart disease models focusing on fibrosis-reversal and functional gain, particularly arrhythmias. This work would promote development of relaxin as a new cardiovascular drug.
Cardiac Dysfunction In Advanced Liver Disease And After Liver Transplantation
Funder
National Health and Medical Research Council
Funding Amount
$128,224.00
Summary
Heart disease is the leading cause of early death after liver transplantation (LT). The scarcity of donor organs means that LT is a limited and valuable resource. We propose screening for heart disease before LT by CT scanning of heart arteries and heart function on stress testing to improve detection of coronary heart disease (CHD). Follow-up CT scans will also assess if LT causes progression of CHD. These studies will aid in development of personalised treatment strategies to improve outcomes.
Oxidative Processes In Vascular Health And Disease
Funder
National Health and Medical Research Council
Funding Amount
$851,980.00
Summary
The process that turns cut fruit brown when it is exposed to air is thought to cause disease of our blood vessels and heart as we age. Despite what we first thought, 'blocking' this oxidation process with antioxidant supplements does not lower heart disease. This is because oxidation not only causes harm but also is useful and essential for normal body function. Our research program aims to show which oxidative processes are needed for blood vessel health or cause vessel disease.
Novel Therapy For Heart Failure With Preserved Ejection Fraction
Funder
National Health and Medical Research Council
Funding Amount
$1,068,984.00
Summary
Heart failure is a major cardiovascular problem. Up to half of the patients have a specific problem with heart muscle relaxation. There is no effective therapy for this type of heart failure. We will investigate the effects of new treatment approach using a range of experimental and clinical methods. If successful the treatment could move quickly into clinical practice.
Heart failure (HF) describes where the heart cannot pump adequately to meet the bodyÍs needs. Mortality remains high; therefore, there is an urgent need for new treatment approaches. The present grant aims to: (1) evaluate treatments for patients at high-risk for future development of HF (2) examine the ability to safely withdraw unnecessary HF drugs (3) focus on the effect of HF on the kidney via novel treatment strategies (4) examine the emerging role of cancer drugs in development of HF.
Improving Outcomes In Heart Failure Through Basic, Clinical And Translational Research
Funder
National Health and Medical Research Council
Funding Amount
$951,005.00
Summary
Heart failure (HF) is a common, chronic cardiovascular condition characterised by a reduced capacity of the heart to function. Patients with HF have a poor quality of life and significantly reduced survival. My proposed programme of research will improve the understanding of heart failure (HF) and lead to better treatments.
Targeting Peroxisome Proliferator-activated Receptor Gamma As A Novel Therapeutic Strategy Against Cerebrovascular Diseases
Funder
National Health and Medical Research Council
Funding Amount
$335,911.00
Summary
High blood pressure and stroke are major health concerns in Australia. Due to the aging population, the incidence of these diseases is expected to rise. This project aims to identify novel molecules that protect cerebral vessels and the brain against the deleterious effects of high blood pressure and stroke. The identification of such molecules may have implications for the development of new therapies and may result in the delay of dysfunction in the brain and improved overall brain health.
Cardiac Dysfunction In Diabetes: A Novel Therapeutic Approach
Funder
National Health and Medical Research Council
Summary
Diabetes is a global epidemic with high mortality associated with heart failure. I propose a new hypothesis: diabetic heart failure reflects a progressive decline in heart pump efficiency due to an accumulation of large glycogen stores in heart muscle cells. This research aims to characterise the underlying causes of heart failure in diabetes and identify intervention potential to rescue function and prevent the progression into failure.
ANNEXIN-A1 MIMETICS: A NOVEL THERAPEUTIC APPROACH FOR TARGETING THE CARDIAC COMPLICATIONS OF DIABETES
Funder
National Health and Medical Research Council
Funding Amount
$815,185.00
Summary
Diabetes affects almost 2 million Australians, creating an increasing heart failure burden. A/Prof Rebecca Ritchie’s team at Baker IDI are interested in the precise role of cardiac inflammation in the progression of cardiomyopathy resulting from diabetes. Using her exciting discovery that a naturally-occurring anti-inflammatory protein is a key regulator of cardiac muscle cell survival and function, A/Prof Ritchie’s team will develop therapies for diabetic cardiomyopathy based on this protein.